Solid tumors encompass a range of cancer types that are named for the type of cells that form them, such as ovarian, breast and lung.
Breast cancer is the most frequently diagnosed cancer in women, excluding cancers of the skin, according to the American Cancer Society (ACS). The ACS estimates that more than 232,600 new cases of invasive breast cancer are expected to be diagnosed among women in the United States during 2014 and 2,360 new cases are expected in men. More than 40,000 people will die from the disease.
Bladder cancer is a type of solid tumor. The ACS estimates that nearly 75,000 new cases of bladder cancer are expected to be diagnosed in the United States during 2014. More than 15,000 people will die from the disease.
Renal cell carcinoma is a type of kidney cancer that starts in the lining of very small tubules in the kidney. The ACS estimates that nearly 64,000 new cases of renal cell carcinoma are expected to be diagnosed in the United States during 2014. Nearly 14,000 people will die from the disease.
Solid Tumors Clinical Trials
Brentuximab vedotin phase 2 trial for CD30-positive non-lymphoma malignancies
Single-agent trial assessing the antitumor activity and safety as well as the relationship of CD30 expression with antitumor activity of brentuximab vedotin in patients with CD30-positive non-lymphoma malignancies, including acute lymphocytic leukemia, acute myeloid leukemia, multiple myeloma, and a number of solid tumors who have failed, refused or have been deemed ineligible for standard therapy. Study #SGN35-013
SGN-LIV1A phase 1 trial for metastatic breast cancer
Single-agent, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1-positive metastatic breast cancer. Study #SGNLVA-001
SGN-CD70A phase 1 trial for renal cell carcinoma
Open-label trial evaluating the safety, tolerability and antitumor activity of SGN-CD70A in relapsed or refractory metastatic renal cell carcinoma. Study #SGN70A-001
ASG-22ME phase 1 trial for solid tumors
Single-agent, dose-escalation trial to evaluate the safety, tolerability, pharmacokinetic profile and antitumor activity of ASG-22ME. Study #AGS-22M6E-11-1
ASG-15ME phase 1 trial for bladder cancer
Single-agent, dose-escalation trial to evaluate the safety, tolerability, pharmacokinetic profile and antitumor activity of ASG-15ME in patients with transitional cell carcinoma of the urothelium (TCCU) (cancer of the bladder, renal pelvis, ureter, or urethra). Study #AGS15E-13-1